Simulations Plus, Inc. — Cyborg Score 7/10

Strategic Profile

The company is a provider of advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Simulations Plus is positioning itself as an AI innovator, hosting an investor day in January 2026 to present new AI product vision and solutions.

Cyborg Score Rationale

FY 2025 saw 13% revenue growth to $79.2M with adjusted EPS of $1.03. AI integration and market expansion into new clinical trial and R&D verticals position the company for sustained growth and margin expansion, though near-term challenges exist from biopharma budget constraints.

Top Insights

• FY 2025 revenue grew 13% to $79.2M with adjusted EPS of $1.03; 2026 guidance reiterated at $79M-$82M
• Company adopted revised Code of Conduct in October 2025 emphasizing responsible AI use
• Expansion into new clinical trial and R&D verticals positions company for larger recurring revenue streams and long-term margin expansion
• Serves pharmaceutical, biotechnology, agrochemical, cosmetics, food companies, and regulatory agencies globally

Named Competitors

• Certara — Drug development software and consulting services
• Schrödinger — AI-driven computational chemistry and drug discovery platform
• Omnicell — Healthcare software and automation solutions

Recent Developments

• (December 2025) FY 2025 results: $79.2M revenue (+13% YoY), adjusted EPS $1.03
• (January 2026) Virtual Investor Day announced to present AI solutions and new product vision
• (October 2025) Revised Code of Conduct emphasizing responsible AI practices adopted by board

Open the full interactive Simulations Plus, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.